Renalytix (RENXF) Stock Price & Analysis
RENXF Stock Chart & Stats
- Day’s Range
- $0.04 - $0.08
- 52-Week Range
- $0.02 - $0.09
- Previous Close
- $0.06
- Volume
- 1,000
- Average Volume (3M)
- 0
- Market Cap
- $48.92M
- Enterprise Value
- $13.29M
- Total Cash (Recent Filing)
- $6.20M
- Total Debt (Recent Filing)
- $5.80M
- Price to Earnings (P/E)
- ―
- Beta
- 0.81
- Next Earnings
- Dec 08, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic + AI Algorithm
KidneyIntelX pairs biomarker assays with an AI-enabled algorithm to deliver clinical decision support for diabetic kidney risk. That combination creates a durable product differentiation and clinical utility that supports adoption by providers and payers, raising switching costs and underpinning recurring per-test demand as care pathways evolve.
Improving Revenue And Gross Margin Trajectory
A meaningful lift in revenue and a step-change gross margin demonstrate improving unit economics of the lab and test offering. Sustainable margin expansion at scale would enable operating leverage, making future incremental revenue more profitable and supporting long-term viability if volume growth continues.
Per-test Reimbursement And Health-system Contracts
A per-test reimbursement model and direct contracts with health systems provide a repeatable commercialization path and revenue visibility as tests are adopted. Durable payer coverage and system agreements can create predictable volume channels and align incentives for disease-management programs over multiple quarters.
Bears Say
Negative Equity And Stressed Capitalization
Negative shareholders' equity reflects cumulative losses and constrains financial flexibility. It increases dependency on external financing, can complicate contracting or partnership negotiations, and is a structural headwind to scaling operations without recurring positive cash flow or material capital injections.
Persistent Heavy Cash Burn
Sustained negative operating and free cash flow requires ongoing financing to fund growth and operations. Even with improvement, the absolute burn relative to revenue scale shortens runway, forces dilution or costly capital raises, and distracts management from commercial execution and scaling clinical adoption.
Profitability Far From Breakeven
An extremely negative net margin signals a cost structure misaligned with current revenues: fixed lab, R&D, and commercial costs far exceed test income. Until volume rises materially or costs are restructured, the business cannot self-fund growth, limiting long-term sustainability and constraining strategic options.
Renalytix News
RENXF FAQ
What was Renalytix’s price range in the past 12 months?
What is Renalytix’s market cap?
When is Renalytix’s upcoming earnings report date?
How were Renalytix’s earnings last quarter?
Is Renalytix overvalued?
Does Renalytix pay dividends?
What is Renalytix’s EPS estimate?
How many shares outstanding does Renalytix have?
What happened to Renalytix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Renalytix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- James R. McCullough
- Employees
- 46
- Website
- renalytix.com
- Address
- 2 Leman Street, London, NY, E1W 9US, GB
Renalytix (RENXF) Earnings & Revenues
RENXF Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.
View all RENXF earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 1 |
| Technical Analysis | 3 | 3 | 1 |
| Moving Averages | 10 | 2 | 0 |
